The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to Bedside, open or download ...
Messenger RNA vaccines The advent of nucleic acid (RNA and DNA) technology used in SARS-CoV-2 vaccines raises the prospect of its future application against other respiratory viruses such as RSV. mRNA vaccines offer a number of advantages over other types of vaccines, such as: (a) a very ...
ImportancePatients with cancer undergoing treatment are at high risk of COVID-19 following SARS-CoV-2 infection; however, their ability to produce an adequate antibody response to messenger RNA SARS-CoV-2 vaccines is unclear. ObjectiveTo evaluate rates of antispike (anti-S) antibody response to ...
This case-control study estimates protection conferred by prior SARS-CoV-2 infection against reinfection with the Omicron variant among community-dwelling
· Zdenek Provaznik6 · Cornelius Knabbe3 · Jan Gummert1 Received: 28 April 2021 / Accepted: 25 May 2021 / Published online: 9 July 2021 © The Author(s) 2021 Abstract Aims Immunocompromised patients have been excluded from studies of SARS-CoV-2 messenger RNA vaccines...
The vaccines, one of which was authorized for emergency use by the U.S. Food and Drug Administration last week, rely on the genetic instructions known as messenger RNA (mRNA). It prompts cells to make a SARS-CoV-2 protein that trains the immune system to recognize the virus. But long ...
The treatment is based on the same principles used in SARS-CoV-2 vaccines, and the scientists say mRNA technology, though still in its infancy in terms of therapeutic application, holds tremendous clinical potential for the management of disease. Messenger RNA carries instructions to cells...
Bollman, B., Nunna, N., Bahl, K.et al.An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection.npj Vaccines8, 58 (2023). https://doi.org/10.1038/s41541-023-00656-4 Download citation Received12 October 2022 ...
The power and portability of these platforms is perhaps most well illustrated by their rapid deployment as vectors for the delivery of vaccines directed against SARS-CoV-2, the viral pathogen responsible for the COVID-19 pandemic (Corbett et al., 2020; Walsh et al., 2020). These synthetic ...
Recent studies3,4 suggest that SARS-CoV-2 spike-specific mucosal IgA antibodies could provide protection against breakthrough infection. However, it remains unclear whether messenger RNA (mRNA)–based vaccines can induce such SIgA responses. Several studies conclude that humoral mucosal ...